Thallium-201 SPECT in advanced non-small cell lung cancer

Basit Öğe Kaydı
dc.authoridKarlikaya, Celal/0000-0001-7084-4987
dc.authoridCermik, Tevfik Fikret/0000-0001-7622-7277
dc.authorwosidKarlikaya, Celal/JMR-3834-2023
dc.authorwosidCermik, Tevfik Fikret/A-9694-2018
dc.contributor.authorÇermik, TF
dc.contributor.authorYüksel, M
dc.contributor.authorKarlikaya, C
dc.contributor.authorDoganay, L
dc.contributor.authorTüre, M
dc.contributor.authorBerkarda, S
dc.date.accessioned2024-06-12T11:09:20Z
dc.date.available2024-06-12T11:09:20Z
dc.date.issued2003
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: The aim of this study was to evaluate the relationship between Tl-201 tumor uptake, chemotherapeutic response, metastasis, p53 status and survival in non-small cell lung cancer (NSCLC). Methods: A total of 23 patients underwent Tl-201 SPECT. In 9 patients, 2nd Tl-201 SPECT study were performed 1 week after the 3rd cycle of chemotherapy (ChT), and early (ER) and delayed (DR) tumor/normal lung ratios and retention indices (RI) were obtained. In 15 patients p53 status was assayed with immuno-histochemical staining. The patients were divided into subgroups after the 3rd cycle of ChT; responders [R(+) (n = 10)] and non-responders [R(-) (n = 13)], distant metastasis [(M-1) n =11] and [(M-0) n = 12], and mutant p53 status [p(+) n = 7, p53(-) n = 8]. Results: The differences for ER, DR and RI values between all of the subgroups were not statistically significant. ER and DR of responders decreased significantly after ChT; from to 2.46 to 1.36 (p = 0.04) and 2.29 to 1.53 (p = 0.04), respectively. In the non-responder group, both ER and DR slightly increased after ChT (p > 0.05). Conclusion: Our results suggest that in NSCLC, there was a weak correlation between higher Tl-201 ratios and positive response to chemotherapy, absence of distant metastasis, and p53(-) status. Significant Tl-201 uptake decrease after chemotherapy indicates that delayed Tl-201 uptake can be used in evaluating the chemotherapeutic response.en_US
dc.identifier.doi10.1007/BF03006603
dc.identifier.endpage374en_US
dc.identifier.issn0914-7187
dc.identifier.issue5en_US
dc.identifier.pmid12971634en_US
dc.identifier.scopus2-s2.0-18144443695en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage369en_US
dc.identifier.urihttps://doi.org/10.1007/BF03006603
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22776
dc.identifier.volume17en_US
dc.identifier.wosWOS:000184960200005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherJapanese Society Nuclear Medicineen_US
dc.relation.ispartofAnnals Of Nuclear Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNon-Small Cell Lung Canceren_US
dc.subjectTl-201 SPECTen_US
dc.subjectChemotherapyen_US
dc.subjectSurvivalen_US
dc.subjectMetastasisen_US
dc.subjectP53en_US
dc.subjectEmission Computed-Tomographyen_US
dc.subjectTc-99m Mibien_US
dc.subjectCarcinomaen_US
dc.subjectIndicatoren_US
dc.subjectPeten_US
dc.subjectAbnormalitiesen_US
dc.subjectExpressionen_US
dc.subjectResistanceen_US
dc.subjectPrognosisen_US
dc.subjectLesionsen_US
dc.titleThallium-201 SPECT in advanced non-small cell lung canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu